

SPECIALTY GUIDELINE MANAGEMENT

KYPROLIS (carfilzomib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
2. Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

B. Compendial Uses

Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. **Multiple Myeloma**

Authorization of 12 months may be granted for treatment of multiple myeloma.

B. **Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma**

Authorization of 12 months may be granted for treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

1. Kyprolis [package insert]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; September 2018.
2. The NCCN Drugs & Biologics Compendium 2018 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed September 04, 2018.
3. The NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (Version 1.2019) 2018 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed September 11, 2018.
4. The NCCN Clinical Practice Guidelines in Oncology Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (Version 2.2019) 2018 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed September 17, 2018.